|
Nature of Business and Basis of Presentation
|
12 Months Ended |
|---|---|
|
Dec. 31, 2014
|
|
| Accounting Policies [Abstract] | |
| Nature of Business and Basis of Presentation |
1. NATURE OF BUSINESS AND BASIS OF PRESENTATION OncoGenex Pharmaceuticals, Inc. (referred to as “OncoGenex,” “we,” “us,” or “our”) is committed to the development and commercialization of new therapies that address treatment resistance in cancer patients. We were incorporated in the state of Delaware and are headquartered in Bothell, Washington and have a subsidiary in Vancouver, British Columbia. Basis of Presentation The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States. The consolidated financial statements include the accounts of OncoGenex Pharmaceuticals, Inc. and its wholly owned subsidiary OncoGenex Technologies, Inc. Liquidity We have historically experienced recurring losses from operations that have generated an accumulated deficit of $160.0 million through December 31, 2014. At December 31, 2014, we had cash, cash equivalents and short-term investments of $47.1 million. |
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). No definition available.
|